Therapeutic Agent against Alzheimer's disease

CNS Neuroscience and Therapeutics

Volumn 18, Issue 7, 2012, Pages 517-523

  Echeverria, Valentina ^a,b   Zeitlin, Ross ^a  

^a Bay Pines VA Healthcare System   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Memory; Tobacco

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; COTININE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450 2A6; GLYCOGEN SYNTHASE KINASE 3BETA; NICOTINE; PROTEIN KINASE B; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE; ANIMAL; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY;

ALZHEIMER DISEASE; ANIMALS; COTININE; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, NICOTINIC;

EID: 84863534359     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00317.x     Document Type: Review

References (120)

1. Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res 1998;117:267-285.
2. Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 2005;15:755-765, ix.
3. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. Exp Rev Neurother 2008;8:1703-1718.
4. Jacobs RW, Duong T, Scheibel AB. Immunohistochemical analysis of the basal forebrain in Alzheimer's disease. Mol Chem Neuropathol 1992;17:1-20.
5. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatr 2001;49:200-210.
6. Rahman S, Lopez-Hernandez GY, Corrigall WA, Papke RL. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol Disord-Dr 2008;7:422-41.
7. Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000;31:131-144.
8. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604.
9. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-388.
10. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Bio Chem 2000;275:5626-5632.
11. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
12. Abbott JJ, Howlett DR, Francis PT, Williams RJ. Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging 2008;29:992-1001.
13. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat Rev 2009;8:733-750.
14. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(2 Suppl 1):S12-8.
15. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 2008;15:2433-2455.
16. Nikolov R. Alzheimer's disease therapy-an update. Drug News Perspect 1998;11:248-255.
17. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Exp Rev Neurother 2009;9:591-598.
18. Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Int Psychogeriatr/IPA 2008;20:800-806.
19. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-397.
20. Gongadze N, Antelava N, Kezeli T, Okudjava M, Pachkoria K. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News 2008;155:44-48.
21. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: A prospective, observational study. CNS drugs 2010;24:163-76.
22. Graves AB, van Duijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(Suppl 2):S48-S57.
23. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996;35:13568-13578.
24. Shim SB, Lee SH, Chae KR, et al. Nicotine leads to improvements in behavioral impairment and an increase in the nicotine acetylcholine receptor in transgenic mice. Neurochem Res 2008;33:1783-1788.
25. Vidal C. Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Mol Chem Neuropathol 1996;28:3-11.
26. Howe MN, Price IR. Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr/IPA. 2001;13:465-475.
27. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999;143:158-165.
28. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-282.
29. Lukas RJ, Changeux JP, Le Novere N, et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401.
30. Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirations. J Med Chem 2005;48:4705-4745.
31. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, Arendash GW. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: Relevance to Parkinson's and Alzheimer's diseases. Biochim Biophys Acta 1999;1454:143-152.
32. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007;74:1192-1201.
33. Echeverria V, Zeitlin R, Burgess S, et al. Cotinine reduces Amyloid-β aggregation and improves memory in Alzheimer's disease mice. J Alzheimer's Dis 2011;24:817-835.
34. Lewis DF, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 1999;133:1-33.
35. Visoni S, Meireles N, Monteiro L, Rossini A, Pinto LF. Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen. Food Chem Toxicol 2008;46:1190-1195.
36. Donato MT, Viitala P, Rodriguez-Antona C, et al. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metabol Dispos 2000;28:1321-1326.
37. Yamanaka H, Nakajima M, Nishimura K, et al. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 2004;22:419-425.
38. Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006;80:282-297.
39. Caldwell WS, Greene JM, Byrd GD, et al. Characterization of the glucuronide conjugate of cotinine: A previously unidentified major metabolite of nicotine in smokers' urine. Chem Res Toxicol 1992;5:280-285.
40. Ghosheh O, Hawes EM. N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. Drug Metabol Dispos 2002;30:991-996.
41. Kuehl GE, Murphy SE. N-glucuronidation of trans-3'-hydroxycotinine by human liver microsomes. Chem Res Toxicol 2003;16:1502-1506.
42. Bramer SL, Kallungal BA. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers 2003;8:187-203.
43. Hukkanen J, Jacob P, 3rd, Benowitz NL. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clinical Pharmacol Thera 2006;80:522-530.
44. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000;378:356-363.
45. Riah O, Courriere P, Dousset JC, Todeschi N, Labat C. Nicotine is more efficient than cotinine at passing the blood-brain barrier in rats. Cell Mol Neurobiol 1998;18:311-318.
46. Lockman PR, McAfee G, Geldenhuys WJ, Van der Schyf CJ, Abbruscato TJ, Allen DD. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J Pharmacol Exp Ther 2005;314:636-642.
47. Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R. Safety of cotinine in humans: Physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 1997;57:643-650.
48. Yamamoto KI, Domino EF. Nicotine-induced EEG and behavioral arousal. Int J Neuropharmacol 1965;4:359-373.
49. Risner ME, Goldberg SR, Prada JA, Cone EJ. Effects of nicotine, cocaine and some of their metabolites on schedule-controlled responding by beagle dogs and squirrel monkeys. J Pharmacol Exp Ther 1985;234:113-119.
50. Zeitlin R, Patel S, Solomon R, Tran J, Weeber EJ, Echeverria V. Cotinine enhances the extinction of contextual fear memory and reduces anxiety after fear conditioning. Behav Brain Res 2012; 228(2):284-293.
51. Terry AV, Jr., Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ. Cotinine, a neuroactive metabolite of nicotine: Potential for treating disorders of impaired cognition. CNS Drug Rev 2005;11:229-252.
52. Buccafusco JJ, Terry AV, Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 2009;78:852-862.
53. Mizuno M, Yamada K, Takei N, et al. Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation. Mol Psychiatry 2003;8:217-224.
54. Sui L, Wang J, Li BM. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn Mem 2008;15:762-776.
55. Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007;53:703-717.
56. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: Studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-181.
57. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002;53:633-640.
58. Jurgensen S, Ferreira ST. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci 2010;40:221-229.
59. Howland RH. Alternative drug therapies for dementia. J Psychosoc Nurs Mental Health Ser 2011;49:17-20.
60. Faghih R, Gfesser GA, Gopalakrishnan M. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Recent Pat CNS Drug Discov 2007;2:99-106.
61. Lopez-Hernandez GY, Thinschmidt JS, Morain P, et al. Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795. Neuropharmacology 2009;56:821-830.
62. Lopez-Hernandez G, Placzek AN, Thinschmidt JS, et al. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 2007;53:134-144.
63. Sattelle DB, Buckingham SD, Akamatsu M, et al. Comparative pharmacology and computational modelling yield insights into allosteric modulation of human alpha7 nicotinic acetylcholine receptors. Biochem Pharmacol 2009;78:836-843.
64. Hu M, Gopalakrishnan M, Li J. Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: Lack of cytotoxicity in PC12 cells and rat primary cortical neurons. Br J Pharmacol 2009;158:1857-1864.
65. Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease? Alzheimers Dement 2009;5:489-491.
66. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol Psychiatr 2001;49:289-299.
67. Briggs CA, McKenna DG, Piattoni-Kaplan M. Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 1995;34:583-590.
68. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995;674:252-259.
69. Sakata M, Wu J, Toyohara J, et al. Biodistribution and radiation dosimetry of the alpha7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans. Nucl Med Biol 2011;38:443-448.
70. Toyohara J, Hashimoto K. alpha7 Nicotinic receptor agonists: Potential therapeutic drugs for treatment of cognitive impairments in Schizophrenia and Alzheimer's disease. Open Med Chem J 2010; 4:37-56.
71. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-1047.
72. Riah O, Dousset JC, Bofill-Cardona E, Courriere P. Isolation and microsequencing of a novel cotinine receptor. Cell Mol Neurobiol 2000;20:653-664.
73. Buccafusco JJ, Shuster LC, Terry AV, Jr. Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine. Neurosci Lett 2007;413:68-71.
74. Buccafusco JJ, Beach JW, Terry AV, Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. JPharmacol Exp Ther 2009;328:364-370.
75. Buccafusco JJ, Terry AV, Jr. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 2003;72:2931-2942.
76. Sekine Y, Takeda K, Ichijo H. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med 2006;6:87-97.
77. Tobiume K, Matsuzawa A, Takahashi T, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001;2:222-228.
78. Bandaru SS, Lin K, Roming SL, Vellipuram R, Harney JP. Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav 2009; 100(3):239-244.
79. Buckingham SD, Jones AK, Brown LA, Sattelle DB. Nicotinic acetylcholine receptor signalling: Roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 2009;61:39-61.
80. Villarreal JS, Barea-Rodriguez EJ. ERK phosphorylation is required for retention of trace fear memory. Neurobiol Learn Mem 2006;85:44-57.
81. Wood MA, Kaplan MP, Park A, et al. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem 2005;12:111-119.
82. Renzoni DA, Pugh DJ, Siligardi G, et al. Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase. Biochemistry 1996;35:15646-15653.
83. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7:261-269.
84. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901.
85. Zhou XW, Winblad B, Guan Z, Pei JJ. Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. J Alzheimers Dis 2009;17:929-937.
86. Mandelkow EM, Drewes G, Biernat J, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS letters 1992;314:315-321.
87. Hernandez F, de Barreda EG, Fuster-Matanzo A, Goni-Oliver P, Lucas JJ, Avila J. The role of GSK3 in Alzheimer disease. Brain Res Bull 2009;80:248-250.
88. Ploski JE, Pierre VJ, Smucny J, et al. The activity-regulated cytoskeletal-associated protein (Arc/Arg3.1) is required for memory consolidation of pavlovian fear conditioning in the lateral amygdala. J Neurosci 2008;28:12383-12395.
89. Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: Regulation, mechanisms, and function. J Neurosci 2008;28:11760-11767.
90. Gusev PA, Cui C, Alkon DL, Gubin AN. Topography of Arc/Arg3.1 mRNA expression in the dorsal and ventral hippocampus induced by recent and remote spatial memory recall: Dissociation of CA3 and CA1 activation. J Neurosci 2005;25:9384-9397.
91. Pintchovski SA, Peebles CL, Kim HJ, Verdin E, Finkbeiner S. The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci 2009;29:1525-1537.
92. Bloomer WA, VanDongen HM, VanDongen AM. Arc/Arg3.1 translation is controlled by convergent N-methyl-D-aspartate and Gs-coupled receptor signaling pathways. J Biol Chem 2008;283:582-92.
93. Park S, Park JM, Kim S, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 2008;59:70-83.
94. Waltereit R, Dammermann B, Wulff P, et al. Arg3.1/Arc mRNA induction by Ca2+ and cAMP requires protein kinase A and mitogen-activated protein kinase/extracellular regulated kinase activation. J Neurosci 2001;21:5484-5493.
95. Plath N, Ohana O, Dammermann B, et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron 2006;52:437-444.
96. Kristensen SE, Thomsen MS, Hansen HH, Timmermann DB, Hay-Schmidt A, Mikkelsen JD. The alpha7 nicotinic receptor agonist SSR180711 increases activity regulated cytoskeleton protein (Arc) gene expression in the prefrontal cortex of the rat. Neurosci letters 2007;418:154-158.
97. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356.
98. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB life 2007;59:332-345.
99. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
100. Echeverria V, Berman DE, Arancio O. Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. Curr Alzheimer Res 2007;4:518-521.
101. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 2007;35(Pt 5):1219-1223.
102. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm 2006;74:505-530.
103. Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011;77:1253-1262.
104. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Bio Chem 2007;282:10311-10324.
105. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Bio Chem 2005;280:5892-5901.
106. De Felice FG, Vieira MN, Saraiva LM, et al. Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of Abeta oligomerization. Faseb J 2004;18:1366-1372.
107. Ferrao-Gonzales AD, Robbs BK, Moreau VH, et al. Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: Trapping low molecular weight oligomeric species. J Bio Chem 2005;280:34747-34754.
108. Zhao W, Wang J, Ho L, Ono K, Teplow DB, Pasinetti GM. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alzheimers Dis 2009;16:49-57.
109. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 2010;58:911-920.
110. Szymanska I, Radecka H, Radecki J, Kaliszan R. Electrochemical impedance spectroscopy for study of amyloid beta-peptide interactions with (-) nicotine ditartrate and (-) cotinine. Biosens Bioelectron 2007;22:1955-1960.
111. Burgess SZR, Gamble-George J, Echeverria V. Cotinine is neuroprotective against beta-amyloid toxicity. J Alzheimer's Assoc 2008;4:T466.
112. Echeverria V, Burgess S, Zeitlin R, et al. Cotinine: A dual-action drug with multiple benefits against Alzheimer's disease Alzheimer's & Dementia. J Alzheimer's Assoc 2010;6:S536-S537.
113. Antzutkin ON, Balbach JJ, Tycko R. Site-specific identification of non-beta-strand conformations in Alzheimer's beta-amyloid fibrils by solid-state NMR. Biophys J 2003;84:3326-3335.
114. Bowman ER, McKennis H, Jr. Studies on the metabolism of (-)-cotinine in the human. J Pharmacol Exp Ther 1962;135:306-311.
115. Borzelleca JF, Bowman ER, McKennis H, Jr. Studies on the respiratory and cardiovascular effects of (-)-cotinine. J pharmacol Exp Ther 1962;137:313-318.
116. Benowitz NL, Kuyt F, Jacob P, 3rd, Jones RT, Osman AL. Cotinine disposition and effects. Clinical Pharmacol Ther 1983;34:604-611.
117. Benowitz NL, Sharp DS. Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 1989;80:1309-1312.
118. Hatsukami D, Lexau B, Nelson D, Pentel PR, Sofuoglu M, Goldman A. Effects of cotinine on cigarette selfadministration. Psychopharmacology 1998;138:184-189.
119. Hatsukami D, Pentel PR, Jensen J, et al. Cotinine: Effects with and without nicotine. Psychopharmacology 1998;135:141-150.
120. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris 2006;99:172-179.